Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Speedel diabetic kidney disease treatment shows promise
Results from the trial of the compound have shown that it decreases urinary albumin excretion rate (UAER) and total cholesterol in patients with diabetic kidney disease when administered
Results from the trial of the compound have shown that it decreases urinary albumin excretion rate (UAER) and total cholesterol in patients with diabetic kidney disease when administered
The methylphenidate transdermal system (MTS) patch was developed by Noven Pharmaceuticals and is licensed to Shire. It combines the active ingredient of methylphenidate with Noven’s patented DOT Matrix
The trial compared the PrimeBoost therapy with lamivudine (marketed by GlaxoSmithKline as Epivir), which is approved for the treatment of hepatitis B. At 14 weeks, Oxxon’s PrimeBoost immunotherapy
According to the company, the rapid decline in plasma hepatitis C virus-RNA levels observed in patients taking VX-950, together with a viral kinetic analysis that projects the potential
Advancis expects to enroll a total of at least 600 patients throughout the 2005/2006 respiratory infection season. The company anticipates completing enrollment by June 2006 and announcing the
According to the FDA, woman using the patch would be exposed to 60% more estrogen than those taking an oral contraceptive pill, and this increase in exposure to
Eyetech’s lead product is Macugen, a treatment for age related macular degeneration (AMD), a leading cause of adult blindness. However, Genentech has recently announced positive preliminary data from
Prostate cancer is the second most common cancer in men after skin cancer and the second leading cause of cancer death in American men, exceeded only by lung
According to the study, Ink4c and Ptch1 genes collaborate to suppress the development of medulloblastoma, the most common pediatric brain tumor. This collaboration between Ink4c and Ptch1 occurs
Interim results from a pivotal phase III study of the drug were recently described in the New England Journal of Medicine as “simply stunning” and “maybe even a